Top

Published in:

01-06-2018 | Original Paper

Fasting Blood Glucose Level in Locally Advanced Non-Small Cell Lung Cancer: a New Prognostic Factor?

Authors: Esra Korkmaz Kirakli, Ufuk Yilmaz, Hasan Yilmaz, Berna Komurcuoglu

Published in: Discover Oncology | Issue 3/2018

Abstract

Hyperglycemia may lead to proliferation, invasion, apoptosis inhibition, migration, and eventually metastasis of cancer cells by several mechanisms. In this study, the effect of hyperglycemia on overall survival (OS), disease-free survival (DFS), and locoregional recurrence (LRR) was investigated in NSCLC. One stage IIIA-IIIB NSCLC patient treated with chemoradiotherapy between 2010 and 2015 was enrolled. Fasting blood glucose (FBG) levels were recorded in pre-treatment, treatment, and post-treatment periods. Median age was 54 years (51–62). Fifty-two patients had squamous cell carcinoma (SCC); 19 had adenocarcinoma. Median follow-up was 19 (11–30), median survival was 19 (13–24), and DFS was 9 (7–11) months. Diabetic patients had shorter survival than non-diabetics 12 (95%CI, 10–14) vs. 25 months (95%CI,18–32), p = 0.005. Number of patients with LRR was also higher in diabetics compared to non-diabetics (8/12 vs. 11/37, p = 0.039). OS was shorter in patients with hyperglycemic-FBG and diabetic-FBG levels in pre-treatment period (log-rank p = 0.03 and 0.023, respectively). Diabetic-FBG level in pre-treatment period was found to be the only independent risk factor for survival. In subgroup analysis, these differences were apparent in SCC (log-rank p = 0.009 for hyperglicemic, log-rank p = 0.017 for diabetic-FBG). LRR was 68% in patients with diabetic-FBG, 36.5% in patients with non-diabetic-FBG in post-treatment period (p = 0.015). Patients with LRR had significantly higher median FBG value in post-treatment period compared to non-relapsing patients, 138 mg/dL (119–228) and 111 mg/dL (99–164), respectively (p = 0.022). The patients with hyperglycemic and diabetic-FBG levels in pre-treatment period had shorter survival compared to normoglycemic ones. The patients with diabetic-FBG level in post-treatment period had higher LRR, and relapsing patients had higher FBG levels in post-treatment period.

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D (2010) Diabetes and cancer: a consensus report. Diabetes Care 33(7):1674–1685. https://doi.org/10.2337/dc10-0666 CrossRefPubMedPubMedCentral

Satija A, Spiegelman D, Giovannucci E, Hu FB (2015) Type 2 diabetes and risk of cancer. BMJ 350(jan02 1):g7707. https://doi.org/10.1136/bmj.g7707 CrossRefPubMed

Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121(4):856–862. https://doi.org/10.1002/ijc.22717 CrossRefPubMed

Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300(23):2754–2764. https://doi.org/10.1001/jama.2008.824 CrossRefPubMedPubMedCentral

Stein KB, Snyder CF, Barone BB, Yeh HC, Peairs KS, Derr RL, Wolff AC, Brancati FL (2010) Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis. Dig Dis Sci 55(7):1839–1851. https://doi.org/10.1007/s10620-009-0944-8 CrossRefPubMedPubMedCentral

Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, Brancati FL, Wolff AC (2011) Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 29(1):40–46. https://doi.org/10.1200/JCO.2009.27.3011 CrossRefPubMed

Seshasai SR et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364(9):829–841CrossRef

LeRoith D, Novosyadlyy R, Gallagher E, Lann D, Vijayakumar A, Yakar S (2008) Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes 116(Suppl 1):S4–S6. https://doi.org/10.1055/s-2008-1081488 CrossRefPubMed

Nerlich AG, Hagedorn HG, Böheim M, Schleicher ED (1998) Patients with diabetes-induced microangiopathy show a reduced frequency of carcinomas. In Vivo 12(6):667–670PubMed

10.

De Giorgio R, Barbara G, Cecconi A, Corinaldesi R, Mancini AM (2000) Diabetes is associated with longer survival rates in patients with malignant tumors. Arch Intern Med 160(14):2217. https://doi.org/10.1001/archinte.160.14.2217 CrossRefPubMed

11.

Hanbali A, al-Khasawneh K, Cole-Johnson C, Divine G, Ali H (2007) Protective effect of diabetes against metastasis in patients with non-small cell lung cancer. Arch Intern Med 167(5):513. https://doi.org/10.1001/archinte.167.5.513-a PubMed

12.

Richardson LC, Pollack LA (2005) Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2(1):48–53. https://doi.org/10.1038/ncponc0062 CrossRefPubMed

13.

Janssen-Heijnen ML et al (2005) Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 55(3):231–240. https://doi.org/10.1016/j.critrevonc.2005.04.008 CrossRefPubMed

14.

Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67(1):7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

15.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer Statistics, 2009. CA Cancer J Clin 59(4):225–249. https://doi.org/10.3322/caac.20006 CrossRefPubMed

16.

Imai H, Kaira K, Mori K, Ono A, Akamatsu H, Matsumoto S, Taira T, Kenmotsu H, Harada H, Naito T, Murakami H, Endo M, Nakajima T, Yamada M, Takahashi T (2015) Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. BMC Cancer 15(1):989. https://doi.org/10.1186/s12885-015-2012-4 CrossRefPubMedPubMedCentral

17.

Varlotto J, Medford-Davis LN, Recht A, Flickinger J, Schaefer E, Shelkey J, Lazar M, Campbell D, Nikolov M, DeCamp MM (2012) Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer. Lung Cancer 75(3):381–390. https://doi.org/10.1016/j.lungcan.2011.07.019 CrossRefPubMed

18.

Warburg O (1956) On the origin of cancer cells. Science 123(3191):309–314. https://doi.org/10.1126/science.123.3191.309 CrossRefPubMed

19.

Dasgupta A, Nomura M, Shuck R, Yustein J (2016) Cancer’s Achilles’ heel: apoptosis and necroptosis to the rescue. Int J Mol Sci 18(1). https://doi.org/10.3390/ijms18010023

20.

Kim JW, Dang CV (2006) Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 66(18):8927–8930. https://doi.org/10.1158/0008-5472.CAN-06-1501 CrossRefPubMed

21.

Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH, Thompson CB (2001) Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 21(17):5899–5912. https://doi.org/10.1128/MCB.21.17.5899-5912.2001 CrossRefPubMedPubMedCentral

22.

Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J, Chen X (2012) A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 11(8):1672–1682. https://doi.org/10.1158/1535-7163.MCT-12-0131 CrossRefPubMed

23.

Gallagher EJ, LeRoith D (2011) Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci 1243(1):54–68. https://doi.org/10.1111/j.1749-6632.2011.06285.x CrossRefPubMed

24.

Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GRS, Chandel NS (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 107(19):8788–8793. https://doi.org/10.1073/pnas.1003428107 CrossRefPubMedPubMedCentral

25.

Agrimi G, Brambilla L, Frascotti G, Pisano I, Porro D, Vai M, Palmieri L (2011) Deletion or overexpression of mitochondrial NAD+ carriers in Saccharomyces cerevisiae alters cellular NAD and ATP contents and affects mitochondrial metabolism and the rate of glycolysis. Appl Environ Microbiol 77(7):2239–2246. https://doi.org/10.1128/AEM.01703-10 CrossRefPubMedPubMedCentral

26.

Semenza GL (2013) HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest 123(9):3664–3671. https://doi.org/10.1172/JCI67230 CrossRefPubMedPubMedCentral

27.

Shyamasundar S, Jadhav SP, Bay BH, Tay SSW, Kumar SD, Rangasamy D, Dheen ST (2013) Analysis of epigenetic factors in mouse embryonic neural stem cells exposed to hyperglycemia. PLoS One 8(6):e65945. https://doi.org/10.1371/journal.pone.0065945 CrossRefPubMedPubMedCentral

28.

Kim HJ, Kim SH, Yun JM (2012) Fisetin inhibits hyperglycemia-induced proinflammatory cytokine production by epigenetic mechanisms. Evid Based Complement Alternat Med 2012:639469PubMedPubMedCentral

29.

Micucci C, Orciari S, Catalano A (2014) Hyperglycemia promotes K-Ras-induced lung tumorigenesis through BASCs amplification. PLoS One 9(8):e105550. https://doi.org/10.1371/journal.pone.0105550 CrossRefPubMedPubMedCentral

30.

Ben-Haim S, Ell P (2009) 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 50(1):88–99. https://doi.org/10.2967/jnumed.108.054205 CrossRefPubMed

31.

Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P, Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26(11):3160–3167CrossRefPubMed

32.

American Diabetes Association (2017) Classification and Diagnosis of Diabetes. Diabetes Care 40, (Suppl 1):S11–S24

33.

Erickson K, Patterson RE, Flatt SW, Natarajan L, Parker BA, Heath DD, Laughlin GA, Saquib N, Rock CL, Pierce JP (2011) Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol 29(1):54–60. https://doi.org/10.1200/JCO.2010.29.3183 CrossRefPubMed

34.

Chu CK, Mazo AE, Goodman M, Egnatashvili V, Sarmiento JM, Staley CA, Galloway JR, Adsay NV, Jacobs S, Kooby DA (2010) Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol 17(2):502–513. https://doi.org/10.1245/s10434-009-0789-6 CrossRefPubMed

35.

Kiderlen M, de Glas NA, Bastiaannet E, Engels CC, van de Water W, de Craen AJM, Portielje JEA, van de Velde CJH, Liefers GJ (2013) Diabetes in relation to breast cancer relapse and all-cause mortality in elderly breast cancer patients: a FOCUS study analysis. Ann Oncol 24(12):3011–3016. https://doi.org/10.1093/annonc/mdt367 CrossRefPubMed

36.

Nomelini RS, Neto AS, Capuci KA, Murta BM, Murta EF (2011) Relationship between plasma glucose levels and malignant uterine cervical neoplasias. Clin Med Insights Oncol 5:77–82. https://doi.org/10.4137/CMO.S6916 CrossRefPubMedPubMedCentral

37.

Tieu MT, Lovblom LE, McNamara MG, Mason W, Laperriere N, Millar BA, Ménard C, Kiehl TR, Perkins BA, Chung C (2015) Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. J Neuro-Oncol 124(1):119–126. https://doi.org/10.1007/s11060-015-1815-0 CrossRef

38.

In Choi J, Chang HK, Lee DW, Lee KH, Park JS, Lee HN (2015) Does diabetes mellitus have an impact on the prognosis for patients with cervical cancer? Gynecol Oncol 139(2):319–323. https://doi.org/10.1016/j.ygyno.2015.09.004 CrossRef

39.

Li J, Wu Mf, Lu Hw, Zhang Bz, Wang Lj, Lin Zq (2016) Impact of hyperglycemia on outcomes among patients receiving neoadjuvant chemotherapy for bulky early stage cervical cancer. PLoS One 11(11):e0166612. https://doi.org/10.1371/journal.pone.0166612 CrossRefPubMedPubMedCentral

40.

Nakazawa K, Kurishima K, Tamura T, Ishikawa H, Satoh H, Hizawa N (2013) Survival difference in NSCLC and SCLC patients with diabetes mellitus according to the first-line therapy. Med Oncol 30(1):367. https://doi.org/10.1007/s12032-012-0367-9 CrossRefPubMed

41.

Luo J, Chen YJ, Chang LJ (2012) Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patients. Lung Cancer 76(2):242–247. https://doi.org/10.1016/j.lungcan.2011.10.019 CrossRefPubMed

42.

Inal A, Kaplan MA, Kucukoner M, Urakcı Z, kılınc F, Isıkdogan A (2014) Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer? Rev Port Pneumol 20(2):62–68. https://doi.org/10.1016/j.rppneu.2013.09.001 CrossRefPubMed

43.

Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P (2003) Impact of comorbidity on lung cancer survival. Int J Cancer 103(6):792–802. https://doi.org/10.1002/ijc.10882 CrossRefPubMed

44.

Hatlen P, Grønberg BH, Langhammer A, Carlsen SM, Amundsen T (2011) Prolonged survival in patients with lung cancer with diabetes mellitus. J Thorac Oncol 6(11):1810–1817. https://doi.org/10.1097/JTO.0b013e31822a75be CrossRefPubMed

45.

Martyn JA, Kaneki M, Yasuhara S (2008) Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. Anesthesiology 109(1):137–148. https://doi.org/10.1097/ALN.0b013e3181799d45 CrossRefPubMed

46.

Fogar P, Pasquali C, Basso D, Floreani A, Piva MG, de Paoli M, Melis A, Sperti C, Pedrazzoli S, Plebani M (1998) Transforming growth factor beta, fibrogenesis and hyperglycemia in patients with chronic pancreatitis. J Med 29(5–6):277–287PubMed

47.

Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA (2006) Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract 12(4):358–362. https://doi.org/10.4158/EP.12.4.358 CrossRefPubMed

48.

Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503):1304–1305. https://doi.org/10.1136/bmj.38415.708634.F7 CrossRefPubMedPubMedCentral

49.

Storozhuk Y, Hopmans SN, Sanli T, Barron C, Tsiani E, Cutz JC, Pond G, Wright J, Singh G, Tsakiridis T (2013) Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer 108(10):2021–2032. https://doi.org/10.1038/bjc.2013.187 CrossRefPubMedPubMedCentral

50.

Coyle C, Cafferty FH, Vale C, Langley RE (2016) Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol 27(12):2184–2195. https://doi.org/10.1093/annonc/mdw410 CrossRefPubMedPubMedCentral

Title: Fasting Blood Glucose Level in Locally Advanced Non-Small Cell Lung Cancer: a New Prognostic Factor?
Authors: Esra Korkmaz Kirakli
Ufuk Yilmaz
Hasan Yilmaz
Berna Komurcuoglu
Publication date: 01-06-2018
Publisher: Springer US
Published in: Discover Oncology / Issue 3/2018
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-018-0322-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Fasting Blood Glucose Level in Locally Advanced Non-Small Cell Lung Cancer: a New Prognostic Factor?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

Thyroid Hormone Promotes β-Catenin Activation and Cell Proliferation in Colorectal Cancer

Thyroid Hormone in the Clinic and Breast Cancer

Type 1 IGF Receptor Localization in Paediatric Gliomas: Significant Association with WHO Grading and Clinical Outcome

Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats

Leptin Involvement in Primary Brain and Pituitary Tumors: Therapeutic Potential, Prognostic Value, and Proposed Diagnostic Application

Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page